Prograf, Protopic(tacrolimus)
Advagraf, Astagraf, Envarsus, Modigraf, Prograf, Protopic, Tacforius, Tacrolimus (tacrolimus) is a small molecule pharmaceutical. Tacrolimus was first approved as Prograf on 1994-04-08. It is used to treat atopic dermatitis and graft vs host disease in the USA. It has been approved in Europe to treat atopic dermatitis, graft rejection, kidney transplantation, and liver transplantation. The pharmaceutical is active against peptidyl-prolyl cis-trans isomerase FKBP1A.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Astagraf, Envarsus, Prograf, Protopic, Tacrolimus (discontinued: Tacrolimus)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Tacrolimus
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ASTAGRAF XL | Astellas Pharma | N-204096 RX | 2013-07-19 | 3 products, RLD, RS |
| PROGRAF | Astellas Pharma | N-050708 RX | 1994-04-08 | 3 products, RLD, RS |
| PROGRAF | Astellas Pharma | N-050709 RX | 1994-04-08 | 1 products, RLD, RS |
| PROGRAF | Astellas Pharma | N-210115 RX | 2018-05-24 | 2 products, RLD, RS |
| PROTOPIC | LEO Pharma | N-050777 RX | 2000-12-08 | 2 products, RLD, RS |
| ENVARSUS XR | Veloxis Pharmaceuticals | N-206406 RX | 2015-07-10 | 3 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| astagraf xl | New Drug Application | 2023-08-25 |
| envarsus | New Drug Application | 2025-02-26 |
| hyaluronic acid sodium salt 1% / niacinamide 4% / tacrolimus 0.1% | unapproved drug other | 2019-04-24 |
| hyaluronic acid sodium salt 1% / tacrolimus 0.1% / urea 20% | unapproved drug other | 2019-05-16 |
| niacinamide 4% / tacrolimus 0.03% | unapproved drug other | 2019-05-16 |
| niacinamide 4% / tacrolimus 0.1% | unapproved drug other | 2019-04-24 |
| prograf | New Drug Application | 2023-08-25 |
| protopic | New Drug Application | 2010-05-24 |
| tacrolimus | ANDA | 2025-03-05 |
| tacrolimus 0.1% | unapproved drug other | 2019-05-09 |
Show 2 more
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| atopic dermatitis | EFO_0000274 | D003876 | L20 |
| graft vs host disease | — | D006086 | D89.81 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
TACROLIMUS, PROGRAF, ASTELLAS | |||
| 2028-07-16 | ODE-360 | ||
| 2025-05-24 | ODE-269, ODE-294 | ||
TACROLIMUS, ASTAGRAF XL, ASTELLAS | |||
| 2025-05-24 | ODE* | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Tacrolimus, Envarsus Xr, Veloxis Pharms Inc | |||
| 8664239 | 2028-08-30 | U-1752, U-2677, U-2678 | |
| 8685998 | 2028-08-30 | DP | U-1752, U-2677, U-2678 |
| 9549918 | 2028-05-30 | DP | |
| 10166190 | 2028-05-30 | DP | |
| 10864199 | 2028-05-30 | U-2677, U-2678 | |
| 11110081 | 2028-05-30 | U-2678 | |
| 11123331 | 2028-05-30 | U-2677 | |
| 11419823 | 2028-05-30 | DP | |
| 7994214 | 2024-08-30 | DP | |
| 8486993 | 2024-08-30 | DP | U-1752 |
| 8586084 | 2024-08-30 | U-1752 | |
| 8591946 | 2024-08-30 | DP | |
| 8617599 | 2024-08-30 | DP | |
| 8623410 | 2024-08-30 | DP | |
| 8623411 | 2024-08-30 | U-1752 | |
| 8889185 | 2024-08-30 | U-1752 | |
| 8889186 | 2024-08-30 | U-1752 | |
| 9161907 | 2024-08-30 | DP | U-1752 |
| 9757362 | 2024-08-30 | DP | |
| 9763920 | 2024-08-30 | DP | |
| 10548880 | 2024-08-30 | U-2677, U-2678 | |
| 11077096 | 2024-08-30 | DP | |
ATC Codes
D: Dermatologicals
— D11: Other dermatological preparations in atc
— D11A: Other dermatological preparations in atc
— D11AH: Agents for dermatitis, excluding corticosteroids
— D11AH01: Tacrolimus
L: Antineoplastic and immunomodulating agents
— L04: Immunosuppressants
— L04A: Immunosuppressants
— L04AD: Calcineurin inhibitors
— L04AD02: Tacrolimus
Clinical
Clinical Trials
1539 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Kidney transplantation | D016030 | — | — | 2 | 11 | 14 | 33 | 9 | 68 |
| Liver transplantation | D016031 | EFO_0010682 | — | — | 7 | 10 | 12 | 2 | 31 |
| Dermatitis | D003872 | — | L30.9 | — | 4 | 6 | 8 | — | 18 |
| Atopic dermatitis | D003876 | EFO_0000274 | L20 | — | 4 | 6 | 7 | — | 17 |
| Eczema | D004485 | — | L30.9 | — | 1 | 3 | 5 | — | 9 |
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | — | — | 1 | 5 | 1 | 7 |
| Arthritis | D001168 | EFO_0005856 | M05-M14 | — | — | 1 | 5 | 1 | 7 |
| Heart transplantation | D016027 | EFO_0010673 | — | — | 3 | 2 | 2 | — | 7 |
| Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | 1 | — | — | 3 | 2 | 6 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | 1 | 3 | — | 3 | — | 6 |
Show 24 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Transplantation | D014180 | — | — | — | — | 3 | — | — | 3 |
| Myasthenia gravis | D009157 | EFO_0004991 | G70.0 | — | — | 3 | — | — | 3 |
| Psoriasis | D011565 | EFO_0000676 | L40 | — | — | 3 | — | — | 3 |
| Transplantation immunology | D014181 | — | — | — | — | 2 | — | — | 2 |
| Host vs graft reaction | D006789 | — | — | — | — | 2 | — | — | 2 |
| Dermatomyositis | D003882 | EFO_0000398 | M33 | — | 1 | 1 | — | 1 | 2 |
| Pneumonia | D011014 | EFO_0003106 | J18 | — | 1 | 1 | — | 1 | 2 |
| Interstitial lung diseases | D017563 | EFO_0004244 | J84.9 | — | 1 | 1 | — | 1 | 2 |
| Polymyositis | D017285 | EFO_0003063 | M33.2 | — | 1 | 1 | — | 1 | 2 |
| Muscle weakness | D018908 | — | — | — | — | 2 | — | — | 2 |
Show 10 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Asthma | D001249 | EFO_0000270 | J45 | — | 3 | — | — | — | 3 |
| Macular degeneration | D008268 | EFO_0001365 | H35.30 | 1 | 1 | — | — | — | 2 |
| Lung transplantation | D016040 | — | — | — | 2 | — | — | — | 2 |
| Bone marrow transplantation | D016026 | — | — | — | 2 | — | — | — | 2 |
| Recurrence | D012008 | — | — | — | 1 | — | — | — | 1 |
| Focal segmental glomerulosclerosis | D005923 | EFO_0004236 | — | — | 1 | — | — | — | 1 |
| Iga glomerulonephritis | D005922 | EFO_0004194 | — | — | 1 | — | — | — | 1 |
| Liver diseases | D008107 | EFO_0001421 | K70-K77 | — | 1 | — | — | — | 1 |
| Virus diseases | D014777 | — | B34 | — | 1 | — | — | — | 1 |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | — | 1 | — | — | — | 1 |
Show 2 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 5 | — | — | — | — | 5 |
| Geographic atrophy | D057092 | — | — | 1 | — | — | — | — | 1 |
| Atrophy | D001284 | — | — | 1 | — | — | — | — | 1 |
| Drug interactions | D004347 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Dried blood spot testing | D059788 | — | — | — | — | — | — | 1 | 1 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Tacrolimus |
| INN | tacrolimus |
| Description | Tacrolimus (anhydrous) is a macrolide lactam containing a 23-membered lactone ring, originally isolated from the fermentation broth of a Japanese soil sample that contained the bacteria Streptomyces tsukubaensis. It has a role as an immunosuppressive agent and a bacterial metabolite. |
| Classification | Small molecule |
| Drug class | immunosuppressives |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC.O |
Identifiers
| PDB | — |
| CAS-ID | 109581-93-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3989887 |
| ChEBI ID | — |
| PubChem CID | 445643 |
| DrugBank | DB00864 |
| UNII ID | Y5L2157C4J (ChemIDplus, GSRS) |
Target
Agency Approved
FKBP1A
FKBP1A
Organism
Homo sapiens
Gene name
FKBP1A
Gene synonyms
FKBP1, FKBP12
NCBI Gene ID
Protein name
peptidyl-prolyl cis-trans isomerase FKBP1A
Protein synonyms
12 kDa FK506-binding protein, 12 kDa FKBP, Calstabin-1, FK506 binding protein 1A, 12kDa, FK506 binding protein12, FK506-binding protein 1, FK506-binding protein 12, FK506-binding protein 1A, FK506-binding protein, T-cell, 12-kD, FKBP-12, FKBP-1A, FKBP12-Exip3, Immunophilin FKBP12, PPIase FKBP1A, protein kinase C inhibitor 2, Rotamase
Uniprot ID
Mouse ortholog
Fkbp1a (14225)
peptidyl-prolyl cis-trans isomerase FKBP1A (Q545E9)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Tacrolimus
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 74,249 documents
View more details
Safety
Black-box Warning
Black-box warning for: Astagraf xl, Envarsus, Prograf, Protopic, Tacrolimus
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
115,584 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use